Abstract
Introduction. Fungal infections caused by yeast have increased in recent decades, becoming a major threat to public health.Hypothesis/Gap Statement. Antifungal therapy represents a challenging problem because, in addition to presenting many side effects, fungal resistance has been increasing in recent years. As a result, the search for new therapeutic agents has advanced with the use of new technologies such as nanoparticles (NPs).Aim. Synthesize, characterize and evaluate the antifungal potential of naringenin (NAR)-stabilized silver NPs.Methodology. The biosynthesis of NPs was stabilized using the NAR molecule and an aqueous solution of silver nitrate. The characterization of silver nanoparticles (AgNPs) was performed using different methods, which include UV-visible spectroscopy, powder X-ray diffraction (XRD), transmission electron microscopy, zeta potential measurements and Fourier transform infrared (FTIR) spectroscopy. Antifungal activity was evaluated against clinical isolates of Candida albicans by determining the MIC and the minimum fungicidal concentration (MFC).Results. The AgNP NAR showed a colloidal appearance with an average size of 14.71 nm and zeta potential measured at -33.3 mV, indicating a highly stable suspension. XRD analysis confirmed the crystal structure. FTIR spectra showed the presence of several functional groups of plant compounds, which play an important role in the coating and bioreduction processes. The antifungal activity against C. albicans showed an MIC of 3.55 µg ml-1 and an MFC of 7.1 µg ml-1. According to the growth kinetic assay in 12 h, there was a reduction of ~50% (<3 log10). Furthermore, AgNP NAR did not show mutagenic potential.Conclusion. The AgNP NAR obtained presented ideal characteristics for biomedical applications, good stability and promising antimicrobial activity.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call